Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer's Disease: Molecular Insight and Clinical Outcome
Authors:
Open Access
- 29 October 2024
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 16 (10) , e72648
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, neurofibrillary tangles, and cognitive decline. Given the shared neuropathophysiological traits between AD and type 2 diabetes mellitus (T2DM), repurposing antidiabetic medications, such as dipeptidyl peptidase 4 inhibitors (DPP4i), has emerged as a promising therapeutic strategy. This review comprehensively evaluates the preclinical and clinical evidence supporting the potential of DPP4i in preventing or treating AD by modulating Aβ and tau pathology, improving cognitive function, reducing neuroinflammation and oxidative stress, and promoting neuronal survival. The beneficial effects of DPP4i are likely mediated through the modulation of insulin signaling, anti-inflammatory and antioxidant properties, glucagon-like peptide-1 (GLP-1) upregulation, and modulation of the amyloidogenic pathway. While further research is needed to establish their clinical efficacy in AD patients, DPP4i offers a promising avenue for therapeutic intervention for this devastating neurodegenerative disease.Keywords
This publication has 42 references indexed in Scilit:
- From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer’s DiseaseMolecular Neurobiology, 2024
- SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse modelBiomedicine & Pharmacotherapy, 2023
- Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta‐analysisDiabetes/Metabolism Research and Reviews, 2023
- Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer’s DiseaseNeurochemical Research, 2023
- Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by VildagliptinColloids and Surfaces B: Biointerfaces, 2022
- A novel DPP‐4 inhibitor Gramcyclin A attenuates cognitive deficits in APP/PS1/tau triple transgenic mice via enhancing brain GLP‐1‐dependent glucose uptakePhytotherapy Research, 2022
- Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier statusAlzheimer's & Dementia, 2020
- Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairmentArchives of Gerontology and Geriatrics, 2019
- The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s diseaseDiabetes Research and Clinical Practice, 2017
- Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s DiseaseMolecular Neurobiology, 2016